Jovanka Vuksanovic, MD
Internal Medicine · North Platte, NENPI 1487744710
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,085 of the $3,833 with a category attached, or 80.5%. 24 manufacturers reported payments, led by Boston Scientific at 29.3% of the total. 2025 is the largest year on record at $1,907, more than ten times the $42 reported in 2020. Among internal medicine clinicians in NE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 110 payments — averaging $34.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$1K
- AbbVie$807
- AstraZeneca$380
- Novo Nordisk$304
- Gilead$228
- Teleflex LLC$143
- plus $850 from 18 others
What the payments were for
- Travel & lodging$74820%
- Food & beverage$3,08580%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 3 | $1,121 |
| AbbVie(2 entities) | 42 | $807 |
| AstraZeneca | 8 | $380 |
| Novo Nordisk | 15 | $304 |
| Gilead | 5 | $228 |
| Teleflex LLC | 1 | $143 |
| Ferring Pharmaceuticals Inc. | 1 | $119 |
| Phathom Pharmaceuticals, Inc. | 1 | $103 |
| Otsuka America Pharmaceutical, Inc. | 5 | $95 |
| Lilly USA, LLC | 6 | $93 |
| Johnson & Johnson | 1 | $75 |
| Exact Sciences | 5 | $70 |
| Grifols USA, LLC | 2 | $60 |
| Astellas Pharma US Inc | 3 | $46 |
| Amgen | 2 | $27 |
| E.r. Squibb & Sons, L.L.C. | 2 | $27 |
| Merck | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Boehringer Ingelheim | 1 | $17 |
| GSK | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
| Novartis | 1 | $13 |
| Integra Lifesciences Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,833 in reported general payments places this provider in the 90th percentile of 570 internal medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 84 | $78,981 |
| EliquisApixaban | 102 | $55,510 |
| JardianceEmpagliflozin | 78 | $47,684 |
| FarxigaDapagliflozin Propanediol | 39 | $26,789 |
| MounjaroTirzepatide | 25 | $24,615 |
| MyrbetriqMirabegron | 22 | $11,984 |
| XareltoRivaroxaban | 12 | $6,832 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $5,706 |
| DapagliflozinDapagliflozin Propanediol | 11 | $5,530 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $5,204 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $4,954 |
| Potassium Chloride | 146 | $3,316 |
| SynthroidLevothyroxine Sodium | 45 | $3,160 |
| Pregabalin | 74 | $1,976 |
| Atorvastatin Calcium | 128 | $1,657 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $304 | $78,98184 claims |
| Boehringer IngelheimJardiance | $17 | $47,68478 claims |
| AstraZenecaFarxiga | $380 | $26,78939 claims |
| Lilly USA, LLCMounjaro | $93 | $24,61525 claims |
| Astellas Pharma US IncMyrbetriq | $46 | $11,98422 claims |
| Johnson & JohnsonXarelto | $75 | $6,83212 claims |
| GSKBreo Ellipta | $16 | $5,20413 claims |
| AbbVieSynthroid | $807 | $3,16045 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 570 internal medicine providers in Nebraska.
Other internal medicine in North Platte
- Brian BoerOmaha$142K
- Sherri ThomasLincoln$136K
- Adam BurdorfOmaha$29K
- David SharpOmaha$26K
- David ShinOmaha$26K
- Nikhil JaganOmaha$20K
- Arman PajnigarPapillion$18K
- Laura FrigyesElkhorn$16K
- John HarrisBellevue$15K
- Aaron WardLincoln$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.